Volume 5.43 | Nov 5

Mesenchymal Cell News 5.43 November 5, 2013
Mesenchymal Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mesenchymal Cell News on Twitter
Therapeutic Potential of Genetically Modified Mesenchymal Stem Cells after Neonatal Hypoxic-Ischemic Brain Damage
Mesenchymal stem cells (MSC) have been shown to improve outcome after neonatal hypoxic ischemic brain injury possibly by secretion of growth factors stimulating repair processes. Scientists investigated whether MSC, modified to secrete specific growth factors, can further enhance recovery. [Mol Ther] Abstract
Request Your Free Wallchart: Mesenchymal Stem Cells (A Nature Reviews Molecular Cell Biology Collaboration)
PUBLICATIONS ( Ranked by impact factor of the journal)
Chondrogenic Differentiation Increases Anti-Donor Immune Response to Allogeneic Mesenchymal Stem Cell (MSC) Transplantation
Investigators showed that allogeneic differentiated MSC lost the ability to inhibit T-cell proliferation in vitro, in association with reduced nitric oxide & prostaglandin E2 secretion. [Mol Ther] Abstract

Microenvironment Mesenchymal Cells Protect Ovarian Cancer Cell Lines from Apoptosis by Inhibiting X-Linked Inhibitor of Apoptosis Protein Inactivation
Carcinoma-associated mesenchymal stem cells (CA-MSC) have been shown to induce ovarian cancer chemoresistance through trogocytosis. Researchers examined CA-MSC properties to protect ovarian cancer cells from carboplatin-induced apoptosis. [Cell Death Dis] Full Article

Human Fetal and Adult Bone Marrow Derived Mesenchymal Stem Cells Use Different Signaling Pathways for the Initiation of Chondrogenesis
Scientists compared the chondrogenic potential of human mesenchymal stem cells (MSCs) isolated from fetal and adult bone marrow and show distinct differences in their responsiveness to specific growth factors. Transforming growth factor beta 3 induced chondrogenesis in adult but not fetal MSCs. [Stem Cells Dev] Abstract

The Role of CCL5 in the Ability of Adipose Tissue-Derived MSC to Support Repair of Ischemic Regions
Researchers isolated mesenchymal stem cells (MSC) from adult tissues – bone marrow, dental tissue and adipose tissue – to compare how auto-transplantation of these MSC effectively supports the repair of bone fracture and ischemic tissue. [Stem Cells Dev] Abstract

Standardization and Safety of Alveolar Bone-Derived Stem Cell Isolation
Cell therapies utilizing mesenchymal stem cells (MSCs) could overcome limitations of traditional treatments for reconstructing craniofacial tissues. Researchers explored a standardized methodology for the isolation and clinical-scale expansion of alveolar bone marrow-derived MSCs. [J Dent Res] Abstract

Osteosarcoma Cells Promote the Production of Pro-Tumor Cytokines in Mesenchymal Stem Cells by Inhibiting Their Osteogenic Differentiation through the TGF-ß/Smad2/3 Pathway
Researchers determined the effects of osteosarcoma cells on both the production of pro-tumor cytokines by mesenchymal stem cells (MSCs) and the osteogenic differentiation of MSCs. They found that osteosarcoma cells promoted the production of IL-6 and VEGF in MSCs by inhibiting their osteogenic differentiation. [Exp Cell Res] Abstract

IL-6 Induces Malignant Transformation of Rat Mesenchymal Stem Cells in Association with Enhanced STAT3 Signaling
Researchers investigated the role of IL-6 and STAT3 signaling in malignant transformation of mesenchymal stem cells (MSCs). They showed that almost all of the MSCs became phenotypically malignant after indirect co-culture with glioma cells, which was confirmed by tumor formation assays when these cells were injected into nude mice. [Cancer Sci] Abstract

Functional and Differential Proteomic Analyses to Identify Platelet Derived Factors Affecting Ex Vivo Expansion of Mesenchymal Stromal Cells
To identify functionally bioactive factors affecting ex vivo mesenchymal stromal cells (MSC) expansion, a differential proteomic approach was performed and identified candidate proteins were evaluated within a bioassay. The differential proteomic approach identified novel platelet derived factors differentially acting on human MSC proliferation. [BMC Cell Biol] Abstract | Full Article

The Role of SDF-1-CXCR4/CXCR7 Axis in Biological Behaviors of Adipose Tissue-Derived Mesenchymal Stem Cells In Vitro
Scientists analyzed the effect of stromal cell-derived factor-1 (SDF-1)/CXCR4 and SDF-1/CXCR7 axis on adipose tissue-derived mesenchymal stem cells (ADSCs) biological behaviors in vitro. Using Flow cytometry and Western blot methods, they found for the first time that CXCR4/CXCR7 expression was increased after treatment with SDF-1 in ADSCs. [Biochem Biophys Res Commun] Abstract

Addition of Mesenchymal Stem Cells Enhances the Therapeutic Effects of Skeletal Myoblast Cell-Sheet Transplantation in a Rat Ischemic Cardiomyopathy Model
Cell sheets of primary skeletal myoblasts (SMBs) of male Lewis rats (r-SMBs), primary mesenchymal stem cells of human female fat tissues (h-MSCs), and their co-cultures were generated using temperature-responsive dishes. The levels of candidate paracrine factors, rat HGF and VEGF, in vitro were significantly greater in the h-MSC/rSMB co-cultures than in those containing r-SMBs only, by real-time PCR and ELISA. [Tissue Eng Part A] Abstract

Non-Adherent Mesenchymal Progenitors from Adipose Tissue Stromal Vascular Fraction
In primary human bone marrow cultures, the initial adherent cell fraction has been shown to provide a microenvironment for self-renewal of primitive non-adherent mesenchymal progenitors (NAMP), with increased differentiation potential compared to adherent Colony Forming Units-fibroblast. Scientists investigated whether NAMP exist also in cultures of stromal vascular fraction cells derived from human adipose tissue. [Tissue Eng Part A] Abstract

Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
Immunobiology of Mesenchymal Stem Cells
The authors focus on the crosstalk between mesenchymal stem cells and immune responses and their potential clinical applications, especially in inflammatory diseases. [Cell Death Differ] Full Article

Three-Dimensional Aggregates of Mesenchymal Stem Cells: Cellular Mechanisms, Biological Properties, and Applications
This article summarizes recent reports of mesenchymal stem cells (MSC) aggregate self-assembly, characterization of biological properties, and their applications in preclinical models. The cellular and molecular mechanisms underlying MSC aggregate formation and functional activation are discussed, and the areas that warrant further investigation are highlighted. [Tissue Eng Part B Rev] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Enter to Win: Free ISCT 2014 Conference Registration in Paris, France!
FDA Clears Commencement of Phase III Chronic Heart Failure Trial Using Mesoblast’s Proprietary Cells
Regenerative medicine company Mesoblast Limited announced that the United States Food and Drug Administration (FDA) has cleared the Investigational New Drug filing made by Mesoblast’s development and commercial partner Teva Pharmaceutical Industries Ltd to commence a Phase III trial in patients with chronic congestive heart failure using Mesoblast’s proprietary Mesenchymal Precursor Cells. [Mesoblast Limited] Press Release

Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
Cellular Biomedicine Group, Inc. announced that it has treated the final patient of its Phase I/IIa clinical trial for ReJoinTM, a human adipose-derived mesenchymal precursor cell (haMPC) therapy for KOA. The trial tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. [Cellular Biomedicine Group] Press Release

Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
Cellular Biomedicine Group announced that their A-StromalTM adipose stromal cell purification kit is ready to launch on the market in China. In addition, they have signed an exclusive China and Hong Kong license for ProCeller computer controlled processing system to extract stem cells from adipose tissue. [Cellular Biomedicine Group] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Molecular Medicine Tri-Conference 2014
February 9-14, 2014
San Francisco, United States

NEW Danish Stem Cell Society’s 3rd Symposium
March 7-8, 2014
Nyborg, Denmark

Visit our events page to see a complete list of events in the mesenchymal cell community.
NEW Postdoctoral Research Fellows – Stem Cells (Wake Forest Institute for Regenerative Medicine)

Postdoctoral Fellowship – Characterizing the Immunosuppressive Impact of Mesenchymal Stem Cells on T Cells (Food and Drug Administration: Center for Biologics Evaluation and Research)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

PhD Student Position – Pro-Tumorigenic Effect of Mesenchymal Stem Cells in Brain Tumors (Ludwig Maximilian University Munich)

Postdoctoral Fellow – Adipose Mesenchymal Stem Cells For Retinal Disease (University of Virginia)

Postdoctoral Research Fellow – Stem Cells (Bioprocessing Technology Institute)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mesenchymal Cell News: Archives | Events | Contact Us